PURPOSE: @entity1619 ( @entity1619 ) is usually @entity2902 (+) and rapidly fatal. Anti- @entity2902 recombinant immunotoxin LMB-2 had phase I activity limited by immunogenicity and rapid growth. To prevent antidrug antibodies and @entity1778 progression between cycles, a phase II trial was performed with LMB-2 after @entity786 and @entity3118 . EXPERIMENTAL DESIGN: @entity1619 @entity1 received @entity786 and @entity3118 days 1 to 3 and 2 weeks later began up to 6 cycles at 3-week intervals of @entity786 and @entity3118 days 1 to 3 followed by LMB-2 30-40  g/kg i.v. days 3, 5, and 7. Three different dose levels of @entity786 and @entity3118 were used, 20+200 (n = 3), 25+250 (n = 12), and 30+300 mg/m(2) (n = 2). RESULTS: Of 17 @entity1 enrolled and treated with @entity3118 and @entity786 for cycle-1, 15 received subsequent cycle(s) containing LMB-2 and were therefore evaluable for response. Lack of antibody formation permitted retreatment in most @entity1 . Of 10 evaluable @entity1778 @entity1 receiving 25+250 or 30+300 mg/m(2) of @entity3118 and @entity786 , 6 (60%) achieved @entity10911 (20%) partial remission (PR), and all 5 with >25% @entity1778 cells achieved CR. No responses were achieved in 5 with @entity1619 or lower @entity3118 and @entity786 doses. Median CR duration for the 6 CRs was 40 weeks. One is without detectable @entity1619 at 47 months. @entity137 was mostly attributable to @entity3118 and @entity786 . Capillary leak from LMB-2 was non-dose limiting. One @entity1 in CR died of a preexisting @entity281 . CONCLUSIONS: LMB-2, administered with @entity3118 and @entity786 to prevent antidrug antibodies and rapid intercycle progression, is highly effective in achieving CR in @entity1778 @entity1619 . @entity3118 and @entity786 dose/schedule is important for safety and efficacy in this high-risk population. Clin Cancer Res; 22(2); 310-8.   2015 AACR.

Complete Remissions of XXXX with Anti- @entity2902 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity10911 :: ('1380', 'Gene') :: ['complete remission (CR) and 2'] @entity1619 :: ('MESH:D015458', 'Disease') :: ['Adult T-cell leukemia', 'lymphomatous ATL', 'ATL'] @entity137 :: ('MESH:D064420', 'Disease') :: ['Toxicity'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity3118 :: ('MESH:C024352', 'Chemical') :: ['Fludarabine', 'fludarabine'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemia', 'leukemic'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity2902 :: ('3559', 'Gene') :: ['CD25']
@entity1619 :: (MESH:D015458,Disease) :: ['Adult T-cell Leukemia']
